Tanvex BioPharma, Inc.
TAI: 6541.TW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen Lam
- Employees
- 139
- Headquarters
- George Town, Cayman Islands
- IPO year
- 2015
- Market cap
- NT$10.4B
- Website
- https://www.tanvex.com
Loading 6541…
Loading profile data…Frequently asked questions about 6541
What does Tanvex BioPharma, Inc. (6541.TW) do?
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which hav...
Where does 6541.TW trade?
Tanvex BioPharma, Inc. (6541.TW) trades on the Taiwan Stock Exchange.
What sector is 6541.TW in?
Tanvex BioPharma, Inc. (6541.TW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tanvex BioPharma, Inc.?
Stephen Lam is the chief executive officer of Tanvex BioPharma, Inc. (6541.TW).
Where is Tanvex BioPharma, Inc. headquartered?
Tanvex BioPharma, Inc. is headquartered in Cayman Islands.
Does 6541.TW pay a dividend?
Tanvex BioPharma, Inc. (6541.TW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6541.TW go public?
Tanvex BioPharma, Inc. (6541.TW) completed its initial public offering in 2015.